Breaking News

Financial Report: Johnson & Johnson

By Kristin Brooks | January 21, 2014

Pharma sales drive growth

Johnson & Johnson

4Q Revenues: $18.4 billion (+5%)

4Q Earnings: $3.5 billion (+37%)

FY Revenues: $71.3 billion (+6%)

FY Earnings: $13.8 billion (+27%)

Comments: Pharmaceutical sales were $7.3 billion in the quarter, up 12%, and $28.1 billion for the year, up 11%. Domestic sales increased 7% in the quarter and 12% for the year. International sales increased 2% in the quarter and 10% for the year. Sales growth was driven by REMICADE and SIMPONI, STELARA, INVEGA SUSTENNA/XEPLION, PREZISTA, DOXIL/CAELYX, and VELCADE, as well as newer products ZYTIGA for metastatic, castration-resistant prostate cancer, XARELTO, an oral anticoagulant, the combined sales of COMPLERA/EVIPLERA, EDURANT for HIV, and INVOKANA for type 2 diabetes. Sales were negatively impacted by loss of exclusivity for ACIPHEX/ PARIET, and CONCERTA. Worldwide Consumer sales were $14.7 billion for the year, up 2%. Worldwide Medical Devices and Diagnostics sales were $28.5 billion, up 4%.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.